CXCR4 and neoplasm: Furthermore, targeting CXCR4 with AMD3100 suppressed tumor growth in vitro and in vivo and synergized with docetaxel in trastuzumab-resistant cell lines and in a trastuzumab-resistant xenograft mouse model [20].